Synthetic Genomics has entered a research and licensing option agreement with Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to apply Synthetic Genomics' proprietary replicon RNA technology toward the design and development of novel RNA-based medicines for specific infectious diseases. The deal was facilitated by Johnson & Johnson Innovation. 

Leveraging its scientific leadership in writing genomes that improve upon or repurpose natural systems, Synthetic Genomics has developed a replicon RNA technology that enables a tunable, multigenic approach to elicit desired antigen expression and immune response for a variety of applications. Synthetic Genomics believes that this technology will enable the development of RNA-based therapies and vaccines that enhance and fine tune immune response against infectious diseases and cancer.

"Our replicon RNA platform is designed to enable controlled expression of antigens and therapeutic proteins to elicit effective immune response against diseases that have historically been difficult to treat or prevent," said Oliver Fetzer, Ph.D., chief executive officer of Synthetic Genomics. "Our expertise in programming viral systems to improve upon natural biological processes is uniquely suited to the aspirations of this collaboration with Janssen."